0.5% More Ani Pharmaceuticals Inc (NASDAQ:ANIP) Shares Shorted

May 16, 2018 - By Elizabeth Jones

Big Money Sentiment decreased to 1.09 in 2017 Q4. It has change of 0.60, from 2017Q3’s 1.69. The ratio is negative due to ANI Pharmaceuticals, Inc. positioning: 13 sold and 43 reduced. 23 funds acquired stakes and 38 increased stakes. Investors holded 6.31 million in 2017Q3 but now own 6.25 million shares or 0.89% less.
Federated Investors Pa holds 189 shs. Deutsche Commercial Bank Ag owns 159,957 shs or 0.01% of their US capital. Cornerstone Capital Mngmt Hldgs Ltd Liability Corporation owns 13,900 shs. Manufacturers Life Insurance The owns 6,280 shs for 0% of their capital. Moreover, Us Bancorporation De has 0% invested in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP). Investment Counselors Of Maryland Limited Liability Corp has invested 0.2% of its capital in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP). Ls Invest Advisors Lc has invested 0.01% in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP). Cortina Asset Ltd Liability Corp reported 0.27% stake. Thomson Horstmann & Bryant holds 0.17% or 20,101 shs. Envestnet Asset holds 3,281 shs or 0% of its capital. Sei Company accumulated 1,435 shs or 0% of the stock. 9,298 were accumulated by Bank Of America De. 24,326 were reported by Cadence Cap Mngmt Limited Co. Caprock holds 4,625 shs or 0.06% of its capital. Amer Intl invested 0% in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP).

ANI Pharmaceuticals, Inc. had 9 insider sales and 0 insider purchases since March 1, 2018. This’s net activity of $15.78 million. On Monday, March 5 4,177 shs were sold by Marken James G., worth $258,640. On Thursday, March 1 $1.47 million worth of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) was sold by PRZYBYL ARTHUR. $439,047 worth of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) was sold by RAYNOR DANIEL on Thursday, March 15. Another trade for 28,652 shs valued at $1.77M was sold by Schrepfer Robert W.

Ani Pharmaceuticals Inc (NASDAQ:ANIP) noted an increase of 0.5% in shorted shares. FINRA published in May ANIP’s total 688,400 shorted shares. Previously was reported up change of 0.5% from 685,000 shares. Former ANIP’s position will need 11 days to recover. It has 65,700 average volume. Ani Pharmaceuticals Inc float short is 7.7%.

ANIP is touching $62.205 during the last trading session, after increased 0.38%.Currently ANI Pharmaceuticals, Inc. is uptrending after 18.93% change in last May 16, 2017. ANIP has 47,324 shares volume. ANIP outperformed by 7.38% the S&P500.

ANI Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, makes, and markets branded and generic prescription pharmaceuticals in the United States.The firm is worth $733.17 million. It focuses on producing controlled substances, anti-cancer , hormones and steroids, and complex formulations.Last it reported negative earnings. The firm offers Erythromycin Ethylsuccinate to treat infections; Esterified Estrogen with Methyltestosterone for treating vasomotor symptoms of menopause; Etodolac to treat pain caused by osteoarthritis, rheumatoid arthritis, and other conditions; Fenofibrate for treating hypercholesterolemia; Flecainide to treat arrhythmia; Fluvoxamine for treating obsessive-compulsive and social anxiety disorders; and Hydrocortisone Enema and Cortenema to treat ulcerative colitis.

A couple more ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) news were announced by: Seekingalpha.com which released on April 27, 2018 “ANI Pharmaceuticals buying assets from Amneal, Impax”, also Streetinsider.com on April 29, 2018 announced “ANI Pharma (ANIP) Agrees to Acquire Generic Products & Other Assets from Amneal Pharmaceuticals LLC and Impax …”, the next Globenewswire.com is “Market Trends Toward New Normal in Viacom, Nutanix, ANI Pharmaceuticals, PACCAR, Cabot Oil & Gas, and Box …” on May 07, 2018. Benzinga.com has article titled “Benzinga’s Daily Biotech Pulse: Valeant Earnings, Lipocine’s FDA Watch, Invivo CFO Departure”.

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.